癌症免疫治疗后关节炎:症状持续时间与治疗反应
该回顾性图表综述纳入10例在Memorial Sloan Kettering Cancer Center接受PD-1、PD-L1和/或CTLA-4抑制剂治疗后出现肌肉骨骼免疫相关不良事件的患者,表现为炎性多关节炎、寡关节炎、腱鞘炎或风湿性多肌痛样表现。所有患者均接受全身糖皮质激素治疗,但6/10仅需泼尼松≤20 mg/日,5例加用保激素药物;末次免疫治疗后关节症状缓解平均需9.2±6.1个月。结论认为肌肉骨骼irAEs症状可持续超过一年,但通常可用低至中等剂量糖皮质激素管理。
要点
- 肌肉骨骼irAEs可表现为类风湿关节炎样多关节炎、寡关节炎、腱鞘炎或风湿性多肌痛。
- 所有患者接受全身糖皮质激素,但6/10仅需泼尼松≤20 mg/日,5例使用保激素药物。
- 末次免疫治疗后关节症状缓解平均需9.2±6.1个月,症状可持续超过一年。
核心结论
- 肌肉骨骼irAEs可表现为RA样多关节炎、寡关节炎、腱鞘炎或风湿性多肌痛,症状可持续超过一年但通常可用低至中等剂量糖皮质激素管理。
研究设计与样本
- 回顾性图表综述,纳入2014至2016年间由单一作者首次接诊的、接受PD-1、PD-L1和/或CTLA-4抑制剂治疗的恶性肿瘤患者中出现的肌肉骨骼irAEs,共10例。
主要发现
- 10例患者平均±SD年龄63.2±9.7岁,7例接受联合检查点抑制剂治疗,3例接受nivolumab单药治疗。
- 4例发生炎性多关节炎,4例寡关节炎,2例腱鞘炎;6例抗核抗体阳性,2例抗环瓜氨酸肽抗体阳性。
- 从首次免疫治疗剂量至关节受累的平均±SD时间为6.3±4.3个月。
- 所有10例均接受全身糖皮质激素治疗,但6/10仅需泼尼松≤20 mg/日;5例接受保激素药物。
- 末次免疫治疗后关节症状缓解的平均±SD时间为9.2±6.1个月。
关键数值与推荐
- 6/10患者仅需泼尼松≤20 mg/日即可管理肌肉骨骼irAEs。
- 末次免疫治疗后关节症状缓解平均±SD时间为9.2±6.1个月。
临床怎么用
- 对接受检查点抑制剂治疗的患者,应警惕炎性多关节炎、寡关节炎、腱鞘炎或风湿性多肌痛样表现。
- 肌肉骨骼irAEs通常可用低至中等剂量糖皮质激素(如泼尼松≤20 mg/日)管理,部分患者需加用保激素药物。
- 关节症状可能持续超过一年,需长期随访并在末次免疫治疗后持续评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Musculoskeletal manifestations of immune-related adverse events (irAEs) after checkpoint inhibitor immunotherapy for cancer remain incompletely characterized and poorly understood. A recently published case series suggested that immunotherapy-induced arthritis is an aggressive process requiring high-dose corticosteroids. METHODS: This was a retrospective chart review of all patients with musculoskeletal irAEs first seen by one of the authors between 2014 and 2016. All patients had been treated for a malignancy with immune checkpoint inhibitors targeting PD-1 (nivolumab, pembrolizumab), PD-L1 (durvalumab), and/or CTLA-4 (ipilimumab, tremelimumab) at Memorial Sloan Kettering Cancer Center. RESULTS: We identified 10 patients with a mean ± SD age of 63.2 ± 9.7 years. Seven were treated with a combination of checkpoint inhibitors and 3 with nivolumab monotherapy. Four patients developed inflammatory polyarthritis, 4 oligoarthritis, and 2 tenosynovitis. Six were antinuclear antibody positive and 2 had anti-cyclic citrullinated peptide antibodies. Mean ± SD time from the first dose of immunotherapy until joint involvement was 6.3 ± 4.3 months. All 10 patients were treated with systemic corticosteroids, but 6 of 10 required ≤20 mg per day of prednisone. Five patients received steroid-sparing agents. Mean ± SD time until resolution of joint symptoms after the last dose of immunotherapy was 9.2 ± 6.1 months. CONCLUSION: Musculoskeletal irAEs can manifest as a rheumatoid arthritis-like polyarthritis, oligoarthritis, tenosynovitis, or polymyalgia rheumatica. Musculoskeletal symptoms can last more than a year, but they can generally be managed with low to moderate doses of corticosteroids.
引用
- Smith MH, Bass AR. Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response. Arthritis Care Res (Hoboken). 2018. PMID: 29125905. doi:10.1002/acr.23467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。